CN1137136C - 定向细胞毒性蒽环型类似物 - Google Patents

定向细胞毒性蒽环型类似物 Download PDF

Info

Publication number
CN1137136C
CN1137136C CNB961986050A CN96198605A CN1137136C CN 1137136 C CN1137136 C CN 1137136C CN B961986050 A CNB961986050 A CN B961986050A CN 96198605 A CN96198605 A CN 96198605A CN 1137136 C CN1137136 C CN 1137136C
Authority
CN
China
Prior art keywords
compound
base
cancer
leu
doxorubicin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB961986050A
Other languages
English (en)
Chinese (zh)
Other versions
CN1202903A (zh
Inventor
A��V��ɳ��
A·V·沙利
ɼ�����
A·A·纳吉
R－Z·凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TURINY EDUCTATION FOUNDATION ADMINISTRATION
Original Assignee
Asta Medica GmbH
Tulaini Education Fund Management Office
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24247176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1137136(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asta Medica GmbH, Tulaini Education Fund Management Office filed Critical Asta Medica GmbH
Publication of CN1202903A publication Critical patent/CN1202903A/zh
Application granted granted Critical
Publication of CN1137136C publication Critical patent/CN1137136C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNB961986050A 1995-11-27 1996-11-14 定向细胞毒性蒽环型类似物 Expired - Lifetime CN1137136C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/562,652 1995-11-27
US08/562,652 US5843903A (en) 1995-11-27 1995-11-27 Targeted cytotoxic anthracycline analogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB021439192A Division CN1166597C (zh) 1995-11-27 1996-11-14 含氮基团的转化方法

Publications (2)

Publication Number Publication Date
CN1202903A CN1202903A (zh) 1998-12-23
CN1137136C true CN1137136C (zh) 2004-02-04

Family

ID=24247176

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB961986050A Expired - Lifetime CN1137136C (zh) 1995-11-27 1996-11-14 定向细胞毒性蒽环型类似物
CNB021439192A Expired - Lifetime CN1166597C (zh) 1995-11-27 1996-11-14 含氮基团的转化方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB021439192A Expired - Lifetime CN1166597C (zh) 1995-11-27 1996-11-14 含氮基团的转化方法

Country Status (27)

Country Link
US (2) US5843903A (2)
EP (2) EP1384710B1 (2)
JP (2) JP3987575B2 (2)
KR (2) KR100445754B1 (2)
CN (2) CN1137136C (2)
AT (2) ATE251179T1 (2)
AU (1) AU709539B2 (2)
BR (1) BR9611647B1 (2)
CA (2) CA2238574C (2)
CZ (1) CZ297297B6 (2)
DE (2) DE69637604D1 (2)
DK (2) DK0863917T3 (2)
EA (1) EA001372B1 (2)
ES (2) ES2310222T3 (2)
HK (1) HK1052920B (2)
HU (1) HU229870B1 (2)
IL (3) IL119691A (2)
IS (2) IS2178B (2)
MX (1) MX9804119A (2)
NO (2) NO324035B1 (2)
NZ (1) NZ322054A (2)
PL (3) PL188786B1 (2)
PT (2) PT1384710E (2)
SK (2) SK284672B6 (2)
UA (1) UA67722C2 (2)
WO (1) WO1997019954A1 (2)
ZA (1) ZA969709B (2)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
IL142869A0 (en) 1998-11-13 2002-03-10 Cyclacel Ltd Transport vectors
FR2786397B1 (fr) * 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
FR2786398B1 (fr) * 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US6380161B1 (en) 1999-06-21 2002-04-30 Inkine Pharmaceutical Company, Inc. Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
JP2003513756A (ja) * 1999-11-12 2003-04-15 アンジオテック ファーマシューティカルズ，インコーポレイテッド 放射性治療と細胞周期インヒビターとの組合せの組成物
ATE344801T1 (de) 1999-12-29 2006-11-15 Immunogen Inc Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
JP2004517034A (ja) * 2000-04-26 2004-06-10 バイオシンセマ インコーポレーテッド （神経）ペプチド結合ｒｇｄ（ａｒｇ−ｇｌｙ−ａｓｐ）
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
KR100420007B1 (ko) * 2001-04-25 2004-03-02 노영쇠 안트라사이클린 유도체 및 이를 포함하는 항암제
BR0212897A (pt) 2001-09-21 2004-08-24 Univ Tulane Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
EP1487493B1 (en) 2002-03-01 2010-01-20 The Administrators of The Tulane Educational Fund Conjugates of cytotoxic agents and biologically active peptides
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
WO2003097083A1 (en) * 2002-05-21 2003-11-27 Daiichi Suntory Pharma Co.,Ltd. Medicinal compositions containing ghrelin
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
EP2075014B9 (en) 2002-05-24 2012-02-01 Angiotech International Ag Compositions and methods for coating medical implants
KR20050084599A (ko) 2002-09-26 2005-08-26 안지오테크 인터내셔날 아게 혈관주위 랩
EP2181704B1 (en) 2002-12-30 2015-05-06 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US20050043215A1 (en) 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
NZ564694A (en) * 2003-04-22 2009-11-27 Sod Conseils Rech Applic Peptide vectors
AU2007221964B2 (en) * 2003-04-22 2008-12-11 Ipsen Pharma S.A.S. Peptide vectors
US7097993B2 (en) 2003-06-25 2006-08-29 Wisconsin Alumni Research Foundation Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity
WO2005086951A2 (en) * 2004-03-10 2005-09-22 Threshold Pharmaceuticals, Inc. Hypoxia-activated anti-cancer agents
US20070060534A1 (en) * 2005-06-30 2007-03-15 Threshold Pharmaceuticals, Inc. Anthracycline analogs
JP5340155B2 (ja) * 2006-09-06 2013-11-13 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞結合分子を有するジソラゾールのコンジュゲート及びそれらの誘導体、新規ジソラゾール誘導体、それらの製法ならびに使用
EP1900742A1 (en) 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
WO2008100591A2 (en) * 2007-02-14 2008-08-21 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
RU2377247C2 (ru) * 2007-12-27 2009-12-27 Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет Молекулярный конъюгат на основе синтетических аналогов люлиберина и его применение в качестве средства доставки днк в клетки гормон-чувствительных опухолей (варианты)
US8742076B2 (en) * 2008-02-01 2014-06-03 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
ES2655243T3 (es) * 2008-04-11 2018-02-19 Tianjin Hemay Oncology Pharmaceutical Co., Ltd Derivados antibióticos de antraciclina con alta actividad, métodos de preparación y usos de los mismos
WO2009124468A1 (zh) * 2008-04-11 2009-10-15 天津和美生物技术有限公司 具有高活性的四环蒽醌类抗生素的衍生物及其制备和应用
CN102159248B (zh) * 2008-07-15 2013-09-11 健泰科生物技术公司 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途
CN102325545A (zh) 2009-02-20 2012-01-18 益普生制药股份有限公司 具有神经肽y受体结合化合物的细胞毒性缀合物
CN102050856B (zh) * 2009-11-03 2014-04-30 天津和美生物技术有限公司 具有高活性的表阿霉素的衍生物及其制备和应用
ES2533710T3 (es) 2010-12-02 2015-04-14 Nerviano Medical Sciences S.R.L. Proceso para la preparación de derivados de morfolinil antraciclina
CN105198966B (zh) * 2014-06-26 2019-06-21 中国人民解放军军事医学科学院毒物药物研究所 GnRH类似物-细胞毒分子缀合物、其制备方法及用途
CA2953371C (en) * 2014-06-30 2021-08-24 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
EP3045540A1 (en) 2015-01-19 2016-07-20 Æterna Zentaris GmbH Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters
JP7057278B2 (ja) 2015-10-28 2022-04-19 ターベダ セラピューティクス インコーポレイテッド Ｓｓｔｒ標的化コンジュゲート及び粒子並びにその製剤
US10450340B2 (en) 2017-02-16 2019-10-22 Monopar Therapeutics Inc. 3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
WO2021068051A1 (en) * 2018-11-13 2021-04-15 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
CA3246188A1 (en) 2022-03-25 2023-09-28 The University Of British Columbia Radiolabeled compounds for in vivo imaging of the gastrin-releasing peptide (GRPR) receptor and treatment of GRPR-related disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725350A (en) * 1972-04-26 1973-04-03 Commercial Soluents Corp Polymeric substances comprising the reaction product of melamine, aldehyde and oxazolidines
US4299822A (en) * 1980-06-09 1981-11-10 Sidney Farber Cancer Institute, Inc. N-Trifluoroacetyladriamycin-14-O-hemiglutarate and -hemiadipate and therapeutic compositions containing same
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
IL106992A (en) * 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5217955A (en) * 1989-09-15 1993-06-08 Biomeasure, Inc. Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin
DK0434960T3 (da) * 1989-12-19 1996-10-14 Pharmacia Spa Chirale 1,5-diiod-2-methoxy- eller benzyloxymellemprodukter
US5304687A (en) * 1989-12-19 1994-04-19 Farmitalia Carlo Erba S.R.L. Morpholinyl derivatives of doxorubicin and process for their preparation
ATE124054T1 (de) * 1990-04-06 1995-07-15 Univ Tulane Somatostatinanaloge.
DK0450461T3 (da) * 1990-04-06 1995-10-23 Univ Tulane LHRH-analoger
JP3169425B2 (ja) * 1992-03-27 2001-05-28 三共株式会社 アジドペンタンサイクリトール
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates

Also Published As

Publication number Publication date
KR100445754B1 (ko) 2004-12-08
AU7572296A (en) 1997-06-19
HUP9903771A2 (hu) 2000-02-28
KR100467899B1 (ko) 2005-01-24
MX9804119A (es) 1998-09-30
EA199800492A1 (ru) 1998-12-24
CN1202903A (zh) 1998-12-23
JP3987575B2 (ja) 2007-10-10
DK1384710T3 (da) 2008-11-17
HK1052920B (zh) 2005-03-04
JP4778405B2 (ja) 2011-09-21
CA2238574C (en) 2004-10-19
EP0863917A1 (en) 1998-09-16
CN1166597C (zh) 2004-09-15
ES2310222T3 (es) 2009-01-01
HU229870B1 (en) 2014-10-28
IS4734A (is) 1998-05-05
IL134685A0 (en) 2001-04-30
PL191781B1 (pl) 2006-07-31
CZ297297B6 (cs) 2006-11-15
EP1384710B1 (en) 2008-07-16
EP0863917B1 (en) 2003-10-01
PL188786B1 (pl) 2005-04-29
PT1384710E (pt) 2008-10-08
NO20051111L (no) 2005-03-01
EP1384710A1 (en) 2004-01-28
IS2634B (is) 2010-06-15
WO1997019954A1 (en) 1997-06-05
CA2238574A1 (en) 1997-06-05
DK0863917T3 (da) 2004-01-19
JP2007045845A (ja) 2007-02-22
NO324035B1 (no) 2007-07-30
EA001372B1 (ru) 2001-02-26
IS2178B (is) 2006-12-15
ATE251179T1 (de) 2003-10-15
DE69630233D1 (de) 2003-11-06
JP2000502055A (ja) 2000-02-22
US5843903A (en) 1998-12-01
KR20040037176A (ko) 2004-05-04
PL326865A1 (en) 1998-10-26
NO982252L (no) 1998-05-15
SK62898A3 (en) 1999-06-11
NZ322054A (en) 1999-04-29
HUP9903771A3 (en) 2000-07-28
ES2205067T3 (es) 2004-05-01
IL119691A (en) 2002-02-10
BR9611647A (pt) 1999-02-23
CA2471775C (en) 2008-01-29
SK284392B6 (sk) 2005-03-04
IL134685A (en) 2002-12-01
US6184374B1 (en) 2001-02-06
NO982252D0 (no) 1998-05-15
ATE401305T1 (de) 2008-08-15
HK1052920A1 (en) 2003-10-03
ZA969709B (en) 1997-08-25
AU709539B2 (en) 1999-09-02
IL119691A0 (en) 1997-02-18
CA2471775A1 (en) 1997-06-05
DE69637604D1 (de) 2008-08-28
UA67722C2 (en) 2004-07-15
PL187230B1 (pl) 2004-06-30
IS8567A (is) 2006-11-09
PT863917E (pt) 2004-02-27
CN1405127A (zh) 2003-03-26
HK1017363A1 (en) 1999-11-19
CZ135798A3 (cs) 1998-10-14
SK284672B6 (sk) 2005-08-04
BR9611647B1 (pt) 2010-03-09
KR19990071672A (ko) 1999-09-27
DE69630233T2 (de) 2004-08-05

Similar Documents

Publication Publication Date Title
CN1137136C (zh) 定向细胞毒性蒽环型类似物
CN1230442C (zh) 5位和6位修饰的促性腺素释放激素拮抗剂
HK1017363B (en) Targeted cytotoxic anthracycline analogs
JP3939354B2 (ja) 抗腫瘍性ペプチド
AU748507B2 (en) Novel synthetic reaction and targeted cytotoxic anthracycline analogs obtained thereby
HK1094586A (en) Novel lhrh-antagonist, production and use thereof as medicament
UA76474C2 (en) Method for conversion of nitrogen of primary aminogroup - or --hydroxy of primary amine into nitrogen of monounsaturated compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ASTA MEDICA AG

Free format text: FORMER OWNER: ASTA DRUG COMPANY SHARES

Effective date: 20020109

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20020109

Address after: Frankfurt, Germany

Applicant after: Zentaris GmbH

Address before: Dresden, Federal Republic of Germany

Applicant before: ASTA Pharma AG.

ASS Succession or assignment of patent right

Owner name: FIGURE LENNY EDUCATION FUND MANAGEMENT OFFICE

Free format text: FORMER OWNER: ASTA MEDICA AG

Effective date: 20030709

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20030709

Address after: American Louis Anna

Applicant after: Turiny Eductation Foundation Administration

Address before: Frankfurt, Germany

Applicant before: Zentaris GmbH

C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20040204

EXPY Termination of patent right or utility model